Sonrotoclax in combination with dexamethasone and daratumumab for t(11;14) relapsed/refractory multiple myeloma: Preliminary safety and efficacy results from the phase 1b/2 BGB-11417-105 study

ASH 2026 • Multiple Myeloma • Sonrotoclax • Oral

Binod Dhakal, MD

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

BGB-11417-105 is an ongoing phase 1b/2 study evaluating investigational sonrotoclax combinations in patients with centrally confirmed t(11;14) relapsed/refractory multiple myeloma (RRMM). This report presents preliminary results from the sonrotoclax plus daratumumab and dexamethasone (SDd) cohort. As of the data cutoff (May 20, 2026), 72 patients received SDd at sonrotoclax doses of 160 mg (n=5), 320 mg (n=33), or 640 mg (n=34). Median prior lines of therapy (PLoT) were 3 (range, 1-10), with 25% having ≥4 PLoT; 56% were triple-class exposed, including 22% triple-class refractory; and 58% had prior anti-CD38 antibody exposure, including 33% with anti-CD38-refractory disease. Median follow-up was 7.2 months (range, 3.3-19.1 months), and 78% of patients remained on treatment at data cutoff. Among 16 patients who discontinued treatment, progressive disease was the most common reason (n=11). Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 64% of patients, including hematologic TEAEs in 33% and infections and infestations in 21% of patients. Neutropenia was the most common grade 3/4 hematologic event at 28%. Two dose-limiting toxicities occurred, and the maximum tolerated dose was not reached. No grade 5 treatment-emergent adverse events were reported. Among 70 efficacy-evaluable patients, the overall response rate (ORR) was 87% (95% CI, 77-94), very good partial response or better (≥VGPR) was 59% (95% CI, 46%-70%), and complete response or better (≥CR) was 23% (95% CI, 14%-34%). In the 320-mg cohort, ORR was 88%, ≥VGPR was 63%, and ≥CR was 22%; in the 640-mg cohort, ORR was 91%, ≥VGPR was 61%, and ≥CR was 24%. Median time to response was 1.0 month (range, 0.9-4.0 months). Median duration of response and progression-free survival were not reached; 12-month rates were 77% (95% CI, 52%-91%) and 69% (95% CI, 46%-84%), respectively.

ClinicalTrials.gov ID: NCT04973605

Population Intervention / Exposure Comparator Outcomes
Patients with centrally confirmed t(11;14) relapsed/refractory multiple myeloma enrolled in an ongoing phase 1b/2 study Sonrotoclax plus daratumumab and dexamethasone N/A
  • Primary endpoint: safety and tolerability
  • Efficacy was assessed by investigators per International Myeloma Working Group criteria

FAQs

BGB-11417-105 evaluated the safety, tolerability, and preliminary efficacy of investigational sonrotoclax with daratumumab and dexamethasone in patients with centrally confirmed t(11;14) relapsed/refractory multiple myeloma (RRMM).

This ongoing phase 1b/2 study enrolled patients with RRMM with centrally confirmed t(11;14). Part 1 enrolled patients with ≥3 prior lines of therapy (PLoT) including a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 antibody; Part 2 enrolled patients with 1-3 PLoT including a PI and IMiD (prior anti-CD38 antibody allowed with exclusions for recent use or refractoriness). Oral sonrotoclax (160, 320, or 640 mg once daily) was administered with oral/intravenous dexamethasone (40 mg once weekly) and subcutaneous daratumumab (1,800 mg per standard schedule; SDd) in 28-day cycles. Dose-limiting toxicities (DLTs) were assessed through day 28 of cycle 1. Treatment-emergent adverse events (TEAEs) were classified per MedDRA v29.0 and graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The primary endpoint was safety and tolerability; efficacy was assessed by investigators per International Myeloma Working Group criteria.

A total of 72 patients with t(11;14) RRMM received SDd (sonrotoclax 160 mg: n=5; 320 mg: n=33; 640 mg: n=34). Median age was 65 years (range, 36-91); 51% were male; 49% were White; and 19% had high-risk cytogenetics. Median PLoT was 3 (range, 1-10), with 25% having ≥4 PLoT. R-ISS stage at initial diagnosis was I in 22%, II in 42%, and III in 17% of patients. Prior anti-CD38 antibody was used in 58%, including 33% with anti-CD38-refractory disease; 56% were triple-class exposed, including 22% triple-class refractory. At data cutoff (May 20, 2026), median follow-up was 7.2 months (range, 3.3-19.1 months), and 56 patients (78%) remained on treatment.

The most common (≥20%) all-grade TEAEs were upper respiratory tract infection (36%), fatigue (31%), neutrophil count decreased (26%), diarrhea (26%), insomnia (25%), and nausea (24%). Grade 3/4 TEAEs occurred in 64%, including grade 3/4 hematologic TEAEs in 33% (most commonly neutropenia [28%]) and grade 3/4 infections and infestations in 21%. Serious adverse events occurred in 29%, most commonly pneumonia (8%). Two DLTs occurred (grade 4 neutropenia at 320 mg; grade 4 thrombocytopenia at 640 mg); the maximum tolerated dose was not reached. No investigator-assessed sonrotoclax-related TEAEs led to sonrotoclax discontinuation. No grade 5 TEAEs were reported. Two patients died during the study (progressive disease; respiratory/circulatory failure), both deemed unrelated to study treatment and occurring more than 30 days after the last dose.

Among 70 efficacy-evaluable patients, overall response rate (ORR) was 87% (95% CI, 77%-94%), very good partial response or better (≥VGPR) was 59% (95% CI, 46%-70%), and complete response or better (≥CR) was 23% (95% CI, 14%-34%). In the 320-mg cohort, ORR was 88%, ≥VGPR was 63%, and ≥CR was 22%; in the 640-mg cohort, ORR was 91%, ≥VGPR was 61%, and ≥CR was 24%. Median time to response was 1.0 month (range, 0.9-4.0 months). Median duration of response (DOR) and progression-free survival (PFS) were not reached; 12-month DOR and PFS rates were 77% (95% CI, 52%-91%) and 69% (95% CI, 46%-84%), respectively.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed